Several lines of evidence suggested that DNA damage repair represented important biomarkers of ICIs therapy, including comutations in homologous recombination repair and mismatch repair,31 mutations in BRCA245 and POLE. 46In addition, RAS/MAPK pathway was associated with immunotherapy in melanoma. Here, POLE is linked to melanoma.